KEROS THERAPEUTICS INC (KROS) Stock Price & Overview
NASDAQ:KROS • US4923271013
Current stock price
The current stock price of KROS is 11.46 USD. Today KROS is up by 1.33%. In the past month the price increased by 0.62%. In the past year, price decreased by -20.41%.
KROS Key Statistics
- Market Cap
- 225.991M
- P/E
- 6.30
- Fwd P/E
- N/A
- EPS (TTM)
- 1.82
- Dividend Yield
- N/A
KROS Stock Performance
KROS Stock Chart
KROS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KROS. When comparing the yearly performance of all stocks, KROS is a bad performer in the overall market: 90.58% of all stocks are doing better.
KROS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to KROS. KROS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
KROS Earnings
On March 4, 2026 KROS reported an EPS of -0.86 and a revenue of 385.00K. The company missed EPS expectations (-34.1% surprise) and missed revenue expectations (-86.31% surprise).
KROS Forecast & Estimates
15 analysts have analysed KROS and the average price target is 23.02 USD. This implies a price increase of 100.9% is expected in the next year compared to the current price of 11.46.
For the next year, analysts expect an EPS growth of -387.72% and a revenue growth -99.86% for KROS
KROS Groups
Sector & Classification
KROS Financial Highlights
Over the last trailing twelve months KROS reported a non-GAAP Earnings per Share(EPS) of 1.82. The EPS increased by 136.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 35.65% | ||
| ROA | 25.74% | ||
| ROE | 28.7% | ||
| Debt/Equity | 0 |
KROS Ownership
KROS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.57 | 362.808B | ||
| AMGN | AMGEN INC | 15.07 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.41 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.88 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.26 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.82 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.8 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KROS
Company Profile
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Company Info
IPO: 2020-04-08
KEROS THERAPEUTICS INC
1050 Waltham Street, Suite 302
Lexington MASSACHUSETTS 02421 US
CEO: Jasbir Seehra
Employees: 78
Phone: 18004831140
KEROS THERAPEUTICS INC / KROS FAQ
What does KROS do?
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
What is the current price of KROS stock?
The current stock price of KROS is 11.46 USD. The price increased by 1.33% in the last trading session.
Does KEROS THERAPEUTICS INC pay dividends?
KROS does not pay a dividend.
What is the ChartMill rating of KEROS THERAPEUTICS INC stock?
KROS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists KROS stock?
KROS stock is listed on the Nasdaq exchange.
How is the market expecting KROS stock to perform?
15 analysts have analysed KROS and the average price target is 23.02 USD. This implies a price increase of 100.9% is expected in the next year compared to the current price of 11.46.